Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Sterilised, Porcine Placental Tissue in the Treatment of Chronic Diabetic Foot Ulcers

NCT05687656 · View on ClinicalTrials.gov ↗

Study Summary

A Prospective, Non-Randomized, Multi-Center Observational Study To determine the safety and effectiveness of InnovaMatrix AC porcine placental ECM therapy for the treatment of chronic, non-healing diabetic foot ulcers (DFUs) Eligible subjects will be treated with a weekly application of sterilized, porcine placental ECM followed by standard of care wound therapy and offloading

Conditions Studied

Interventions

  • DEVICE InnovaMatrix AC porcine placental ECM therapy

Study Locations (5)

Texas

  • SerenaGroup Austin Research Center — Austin
  • Atrium Medical Center — Stafford

Florida

  • Three Rivers Hyperbaric and Wound Center — North Port

New York

  • Serena Group Buffalo Research Center — Buffalo

Pennsylvania

  • SerenaGroup Monroeville — Monroeville

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-10-06
Est. Completion 2025-12-31
Phase NA

Sponsor

ConvaTec

10 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05687656

The ClinicalTrials.gov registry entry for NCT05687656 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ConvaTec, which has 10 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 1 intervention — of which InnovaMatrix AC porcine placental ECM therapy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05687656 reports 5 study locations spanning 4 distinct geographic areas — top geographies include Texas, Florida, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05687656 about?

NCT05687656 is a clinical study titled "Sterilised, Porcine Placental Tissue in the Treatment of Chronic Diabetic Foot Ulcers". A Prospective, Non-Randomized, Multi-Center Observational Study To determine the safety and effectiveness of InnovaMatrix AC porcine placental ECM therapy for the treatment of chronic, non-healing diabetic foot ulcers (DFUs) Eligible subjects will be treated with a weekly application of sterilized...

What is the current status of trial NCT05687656?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-10-06. Estimated completion is 2025-12-31.

What conditions does trial NCT05687656 study?

This clinical trial studies the following conditions: Diabetic Foot Ulcer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05687656?

The interventions under investigation include: InnovaMatrix AC porcine placental ECM therapy (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05687656?

This trial is sponsored by ConvaTec, which has 10 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05687656 being conducted?

This trial has 5 study locations across Florida, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial